dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Walo-Delgado, Paulette Esperanza |
dc.contributor.author | Medina, Silvia |
dc.contributor.author | Quintana, Ester |
dc.contributor.author | Fernández-Velasco, José Ignacio |
dc.contributor.author | Montalban Gairín, Xavier |
dc.contributor.author | Midaglia Fernandez, Luciana |
dc.contributor.author | Sainz de la Maza, Susana |
dc.contributor.author | Comabella Lopez, Manuel |
dc.contributor.author | Monreal, Enric |
dc.date.accessioned | 2022-05-06T12:35:00Z |
dc.date.available | 2022-05-06T12:35:00Z |
dc.date.issued | 2021-10 |
dc.identifier.citation | Walo-Delgado PE, Monreal E, Medina S, Quintana E, Sainz de la Maza S, Fernández-Velasco JI, et al. Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With Alemtuzumab. Front Immunol. 2021 Oct;12:760546. |
dc.identifier.issn | 1664-3224 |
dc.identifier.uri | https://hdl.handle.net/11351/7490 |
dc.description | Limfòcits B; Alemtuzumab; Autoimmunitat |
dc.description.sponsorship | This work was supported by grants from Red Española de Esclerosis Múltiple (REEM) (RD16/0015/0001; RD16/0015/0004; RD16/0015/0006; RD16/0015/0013) and PI18/00572 integrated in the Plan Estatal I+D+I and co-funded by ISCIII-Subdirección General de Evaluación and Fondo Europeo de Desarrollo Regional (FEDER, “Una manera de hacer Europa”). |
dc.language.iso | eng |
dc.publisher | Frontiers Media |
dc.relation.ispartofseries | Frontiers in Immunology;12 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Esclerosi múltiple - Tractament |
dc.subject | Cèl·lules B |
dc.subject | Autoimmunitat |
dc.subject.mesh | Multiple Sclerosis, Relapsing-Remitting |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | B-Lymphocytes |
dc.title | Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With Alemtuzumab |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3389/fimmu.2021.760546 |
dc.subject.decs | esclerosis múltiple recurrente-remitente |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | linfocitos B |
dc.relation.publishversion | https://doi.org/10.3389/fimmu.2021.760546 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Walo-Delgado PE, Medina S, Fernández-Velasco JI] Department of Immunology, Ramón y Cajal University Hospital, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Red Española de Esclerosis Múltiple (REEM), Madrid, Spain. [Monreal E, Sainz de la Maza S] Department of Neurology, Ramón y Cajal University Hospital, IRYCIS, Red Española de Esclerosis Múltiple (REEM), Madrid, Spain. [Quintana E] Neuroimmunology and Multiple Sclerosis Unit, Neurology Department, Neurodegeneration and Neuroinflammation Research Group, Biomedical Research Institute (IDIBGI), Red Española de Esclerosis Múltiple (REEM), Girona, Spain. [Comabella M, Montalban X, Midaglia L] Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Red Española de Esclerosis Múltiple (REEM), Barcelona, Spain |
dc.identifier.pmid | 34691084 |
dc.identifier.wos | 000710902500001 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/RD16%2F0015%2F0004 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |